Law360, New York (April 05, 2010, 7:36 PM ET) -- A federal judge has narrowed the allegations in an investor class action against biopharmacuetical company NeoPharm Inc. over allegedly false and misleading statements about the cancer drug liposome-encapsulated paclitaxel.
Judge Joan Lefkow of the U.S. District Court for the Northern District of Illinois signed off on an opinion and order partially granting and partially denying the defendants' bid for summary judgment on Wednesday.
Judge Lefkow granted the summary judgment bid with respect to all statements made before Jan. 14, 2002, but denied it as to four...
NeoPharm Investors' Class Action Trimmed
To view the full article, take a free trial now.
